MIRA
INFORM REPORT
|
Report Date : |
07.02.2012 |
IDENTIFICATION DETAILS
|
Name : |
MARPEL PHARMA HONDURAS SA |
|
|
|
|
Registered Office : |
Edificio Torre Alpha Local
101, Colonia Lomas Del Gujarro, Tegucigalpa, Republica De Honduras |
|
|
|
|
Country : |
Honduras |
|
|
|
|
Date of Incorporation : |
Not Available |
|
|
|
|
Legal Form : |
Sociedad Anonima |
|
|
|
|
Line of Business : |
Commercialization of pharmaceutical products. |
|
|
|
|
No. of Employees : |
Not Available |
RATING & COMMENTS
|
MIRA’s Rating : |
Ca |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
Status : |
Undetermined |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
Honduras |
C2 |
C2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
GEOPOLITICS – HONDURAS
|
POLITICAL DATA |
ECONOMIC DATA |
|
|
Form of Government: Presidential Republic
|
Currency: Honduras (HNL) 100(HNL)=5.24(USD) |
IDENTIFICATION
|
Legal Name: |
Marpel Pharma Honduras SA |
|||
|
|
|
|||
|
Legal Address |
Edificio Torre Alpha Local
101, Colonia Lomas Del Gujarro, Tegucigalpa, Republica De Honduras (not verified) |
|||
|
|
|
|||
|
Telephone: |
(506) 2290 5780 in Costa Rica (Headquarters, invalid) |
RTN : |
N.A. |
|
|
Fax: |
(506) 2290-5781 in Costa Rica (Headquarters, invalid) |
Legal Form: |
Sociedad Anonima |
|
|
Email: |
Registered in: |
N.A. |
||
|
Website: |
Date Created: |
N.A. |
||
|
Manager: |
Philip Unger Manager in Costa Rica Headquarters |
Date Incorporated: |
N.A. |
|
|
Staff: |
N.A. |
Stock: |
N.A. |
|
|
|
|
Value: |
N.A. |
|
|
Activity: |
Commercialization of pharmaceutical products. |
|||
BANKS
|
Name of the Bank |
Banco Promerica |
|
|
Comments |
The bank does not disclose information of their clients due to
confidentiality. |
|
BUSINESS
|
||
|
PRINCIPAL ACTIVITY |
||
|
|
In regards to the order for a commercial report on the subject, we
inform you that it was not possible to deliver a full report. There is no
telephone number provided in the order, and we haven’t been able to find one.
A search with the address provided Edificio Torre Alpha-Local 101 Colonia
Lomas Del Gujarro Tegucigalpa Honduras, Rupublica De Honduras, was
unsuccessful. We found the headquarters in Costa Rica and found the contact
information in the website: MARPEL PHARMA Headquarters Edificio Multibodegas Bodega # 7 Del Cruce de Multiplaza Escazú 800 metros Noroeste, San José, Costa Rica TEL (506) 2290 5780 (Invalid) Fax (506) 2290-5781 (Invalid) We tried to find other working numbers without success. We sent an e-mail with our request to the e-mail address provided in
the website: info@marphelpharma.com,
mdc@amnet.co.cr,
but have received no answer yet. We have tried several searches in Honduran and Costa Rican government
agencies, institutions and chambers in order to find contact information,
without success. Further research developed over the internet and other sources
provided no additional information. At this point we are unable to verify the information found on the
internet or if the company is active in Honduras. Should you have further
data that would help us contact the company, we will be glad to resume with
the investigation. |
|
Shareholders - Manager - Related Companies
|
Listed at the stock exchange: |
||
|
|
NO |
|
|
Shareholders Parent Company(ies): |
||
|
|
MARPEL PHARMA Headquarters Edificio Multibodegas Bodega # 7 Del Cruce de Multiplaza Escazú 800 metros Noroeste, San José, Costa Rica (Not Verified) |
|
|
Management: |
||
|
|
Philip Unger: General Manager (Headquarters Costa Rica) (not verified) |
|
|
Related Companies: |
||
|
|
Marpel Pharma El Salvador SA de CV (Could not find contact
information) |
|
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.48.67 |
|
|
1 |
Rs.76.75 |
|
Euro |
1 |
Rs.63.56 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.